Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.10 USD

87.10
5,960,499

+0.90 (1.04%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $87.11 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Masimo (MASI) Gets Favorable Ruling in Apple Watch Patent Suit

A U.S. Administrative Law Judge ruled that Apple watches infringe one of Masimo's (MASI) pulse oximeter patents. An import ban may follow for Apple watches.

QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen

QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.

Illumina (ILMN), Nashville Biosciences Partner With Amgen

Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.

Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind

Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.

Abbott's (ABT) New Launch to Boost Blood Donation Experience

Abbott's (ABT) mixed reality offers donors an innovative, immersive digital experience while giving blood.

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

Investors are optimistic about SmileDirectClub (SDC) on continued strategic partnerships and expansion in the teledentistry space.

LabCorp (LH) Oncology Arm Gains Traction, Margin Pressure Stays

In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Sheraz Mian headshot

Top Research Reports for Caterpillar, Equinor & GSK

Today's Research Daily features new research reports on 16 major stocks, including Caterpillar Inc. (CAT), Equinor ASA (EQNR) and GSK plc (GSK).

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.

Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up

Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.

Alcon (ALC) Gains From Innovation, Faces FX Challenges

Alcon's (ALC) Surgical franchise continues to lead the market with its portfolio of advanced technology, intraocular lenses, a substantial installed base of equipment and a growing consumable base.

AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.

Here's Why You Should Retain Ecolab (ECL) Stock for Now

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

Bruker's (BRKR) New Tie-Up to Expand Its U.S. CRO Business

Bruker's (BRKR) latest partnership is expected to expand its CRO business in the United States, benefiting more biopharma and diagnostics companies using unbiased proteomics for decision-making.

Walgreens Boots (WBA) Q1 Earnings Top, Revenues View Up

The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.

Here's Why You Should Hold Cigna (CI) Stock in Your Portfolio

Cigna (CI) remains well-poised for growth on the back of the solid Evernorth and Cigna Healthcare businesses, an expanding customer base and robust cash-generating abilities.

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.

Masimo's (MASI) SpHb During Elective CS Favored by New Study

Masimo's (MASI) SpHb is likely to indicate clinically acceptable accuracy of Hb measurement even at low Hb levels in patients undergoing CS with antepartum hemorrhage.

Here's Why You Should Retain PacBio (PACB) Stock for Now

PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

PETQ vs. BSX: Which Stock Is the Better Value Option?

PETQ vs. BSX: Which Stock Is the Better Value Option?

Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?

Walgreens' (WBA) strategic executions on both the United States and the international front are likely to have contributed to the Q1 2023 top line.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Here's Why You Should Retain Boston Scientific (BSX) For Now

Investors are optimistic about Boston Scientific (BSX), led by new strategic investments and the robust performance of the WATCHMAN device.

PETQ or BSX: Which Is the Better Value Stock Right Now?

PETQ vs. BSX: Which Stock Is the Better Value Option?